Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Drug: Activase
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 72 results found since Jan 2013.
What are the risks of intracerebral haemorrhage due to alteplase after acute ischaemic stroke? Results from an individual patient data meta-analysis of randomised trials
【Background】Alteplase also increases the risk of intracerebral haemorrhage, but the factors determining the proportional and absolute risks are uncertain.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: William Whiteley Source Type: research
Icatibant as a Potential Treatment of Life-Threatening Alteplase-Induced Angioedema
Severe orolingual angioedema is a life-threatening complication of alteplase treatment for acute ischemic stroke that occurs during alteplase infusion or in the first 2 hours afterward. Currently, there are no proven therapies, although glucocorticoids, antihistamines, and adrenaline are sometimes used. Intubation is required if significant airway compromise supervenes. The incidence is .2%-5.1%, and risk factors include treatment with angiotensin-converting enzyme inhibitors and total insular infarcts.
Source: Journal of Stroke and Cerebrovascular Diseases - October 30, 2017 Category: Neurology Authors: Edmund Cheong, Lizzie Dodd, William Smith, Timothy Kleinig Tags: Case Studies Source Type: research
Safety of Intravenous Thrombolysis in Chronic Intracranial Hemorrhage: A Five-Year Multicenter Study
Although the recently updated U.S. alteplase label removed “history of intracranial hemorrhage (ICH)” as a contraindication, there are very limited data on the safety of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with chronic ICH. We sought to evaluate IVT safety in AIS patients with a history of ICH.
Source: Journal of Stroke and Cerebrovascular Diseases - October 31, 2017 Category: Neurology Authors: Ramin Zand, Georgios Tsivgoulis, Alireza Sadighi, Mantinderpreet Singh, Michael McCormack, Shima Shahjouei, Nitin Goyal, Nariman Noorbakhsh-Sabet, Anne W. Alexandrov, Andrei V. Alexandrov Source Type: research
Hemilingual Angioedema after Thrombolysis in a Patient on an Angiotensin II Receptor Blocker
We report a case of a 60-year-old male presenting with hyperacute ischemic stroke developing hemilingual edema after thrombolysis. He was previously maintained on an angiotensin II receptor blocker (ARB), losartan. The swelling resolved over 2 days with immediate administration of intravenous steroids and antihistamine drugs.
Source: Journal of Stroke and Cerebrovascular Diseases - February 13, 2019 Category: Neurology Authors: Jose Danilo Bengzon Diestro, Lady Scarlette Pacsi Sedano, Nikolai Gil Diwa Reyes, Maria Cristina Zarsadias San Jose Tags: Case Report Source Type: research
Corrigendum to “Comparative Analysis of Fibrinolytic Properties of Alteplase, Tenecteplase and Urokinase in an in Vitro Clot Model of Intracerebral Haemorrhage. Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 9 (September), 2020: 105073”
The authors regret an error in the author list, and this should appear as above. The authors regret any inconvenience caused.
Source: Journal of Stroke and Cerebrovascular Diseases - October 27, 2020 Category: Neurology Authors: Naureen Keric, Melanie Doebel, Harald Krenzlin, Elena Kurz, Yasemin Tanyildizi, Axel Heimann, Jochem Koenig, Oliver Kempski, Florian Ringel, Julia Masomi-Bornwasser Source Type: research
Effects of Edaravone, a Free Radical Scavenger, on Circulating Levels of MMP-9 and Hemorrhagic Transformation in Patients with Intravenous Thrombolysis Using Low-dose Alteplase
Matrix metalloproteinase-9 (MMP-9) plays a key role for the blood–brain barrier disruption and intravenous tissue plasminogen activator (iv-tPA) therapy increases MMP-9. Edaravone, a free radical scavenger, reduces MMP-9–related blood–brain barrier disruption. We aimed to investigate whether edaravone would suppress the MMP-9 increase after iv-tPA using low-dose alteplase (0.6 mg/kg).
Source: Journal of Stroke and Cerebrovascular Diseases - October 2, 2014 Category: Neurology Authors: Atsushi Tsuruoka, Chihiro Atsumi, Heisuke Mizukami, Takeshi Imai, Yuta Hagiwara, Yasuhiro Hasegawa Source Type: research
Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours
An intravenous recombinant tissue plasminogen activator (rt-PA, alteplase .6 mg/kg) for acute cerebral infarction within 3 hours of onset was approved in Japan in 2005. The treatment window was subsequently extended to within 4.5 hours of onset. However, few Japanese studies have compared the efficacy and safety of rt-PA therapy between patients treated within 3 hou rs and patients treated within 3-4.5 hours.
Source: Journal of Stroke and Cerebrovascular Diseases - December 5, 2017 Category: Neurology Authors: Ichiro Deguchi, Norio Tanahashi, Masaki Takao Source Type: research
Rectus Sheath Hematoma Following Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Cerebral Infarction: A Case Report
A 76-year-old Japanese man was admitted to our department because of aphasia and right hemiparesis. Brain magnetic resonance imaging showed cerebral infarction caused by occlusion of the left middle cerebral artery, and alteplase therapy was started. Thrombectomy was subsequently performed, resulting in recanalization. On day 4 after admission, he complained of epigastric pain when coughing. On day 8, contrast-enhanced computed tomography showed a left abdominal rectus sheath hematoma without extravasation.
Source: Journal of Stroke and Cerebrovascular Diseases - August 16, 2018 Category: Neurology Authors: Tatsuya Ueno, Takashi Nakamura, Hiroki Hikichi, Akira Arai, Chieko Suzuki, Masahiko Tomiyama Tags: Case Report Source Type: research
Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models
Objective: Thrombolytic therapy with intravenous alteplase (IV-rtPA) has a known risk of symptomatic intracerebral hemorrhage (sICH). We aim to identify factors with a significant association with the development of sICH post-IV-rtPA. We also aim to perform an external validation of sICH predicting scores in our patient population. Material and Methods: We performed a retrospective chart review of patients who received IV-rtPA at our tertiary care hospital. We excluded patients who underwent mechanical thrombectomy.
Source: Journal of Stroke and Cerebrovascular Diseases - September 5, 2019 Category: Neurology Authors: Taha Nisar, Rajanigandhi Hanumanthu, Priyank Khandelwal Source Type: research
Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage
Hematoma lysis with recombinant tissue plasminogen activator (rtPA) has emerged as an alternative therapy for spontaneous intracerebral and intraventricular haemorrhage (ICH and IVH). However, the MISTIE III and CLEAR III trial failed to show significant improvement of favourable outcomes. Besides experimental and clinical trials revealed neurotoxic effects of rtPA. The demand for optimization of fibrinolytic therapy persists. Herein, we used our recently devised clot model of ICH to systematically analyse fibrinolytic properties of rtPA, tenecteplase and urokinase.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: Naureen Keric, Melanie D öbel, Harald Krenzlin, Elena Kurz, Yasemin Tanyildizi, Axel Heimann, Jochem König, Oliver Kempski, Florian Ringel, Julia Masomi-Bornwassser Source Type: research
M2 segment thrombectomy is not associated with increased complication risk compared to M1 segment: A meta-analysis of recent literature
Numerous trials report safety and efficacy of mechanical thrombectomy (MT) for infarcts involving the M1 segment of the middle cerebral artery (MCA; extending from the terminal bifurcation of the internal carotid artery proximally to the main bifurcation distally) in comparison to intravenous thrombolytic therapy (e.g. alteplase) therapy alone.1 –5 The Highly Effective Reperfusion Using Multiple Endovascular Devices (HERMES) meta-analysis of these early studies reported a number needed to treat of 2.6 for MT to reduce the modified Rankin Scale (mRS) by 1 point.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: Christopher Alexander, Andrew Caras, William Kyle Miller, Rizwan Tahir, Tarek R. Mansour, Azedine Medhkour, Horia Marin Source Type: research
Benefits and Safety of Periprocedural Heparin During Thrombectomy in Patients Contra-Indicated for Alteplase
Role of peri-procedural heparin as an adjuvant treatment during mechanical thrombectomy (MT) for patients contra-indicated for alteplase remains a source of debate.
Source: Journal of Stroke and Cerebrovascular Diseases - August 11, 2020 Category: Neurology Authors: Sol ène Hebert, Pierre Clavel, Benjamin Maier, Katsuhiro Mizutani, François Delvoye, Bertrand Lapergue, Malek Ben Maacha, Robert Fahed, Simon Escalard, Jean-Philippe Desilles, Hocine Redjem, Gabriele Ciccio, Stanislas Smajda, Raphael Blanc, Michel Pioti Source Type: research
